Weekly influenza cases nearly double in Maine over last 3 weeks
Feb. 19—Influenza continues to spread rapidly in Maine, with more than 2,000 confirmed cases last week, the Maine Center for Disease Control and Prevention said.
Maine recorded 2,028 cases of influenza for the week ending Feb. 15, the highest so far in the 2024-25 flu season, and about double the number of weekly cases Maine reported three weeks earlier. Flu season runs from October to May, and while the peak of the season can vary, February is often a month when Maine will experience the most new infections.
For the previous week, ending Feb. 8, the Maine CDC reported 1,916 cases.
Hospitalizations for influenza have also climbed, with 145 last week, and 711 total hospitalizations for the season.
Most of the state is considered to be in the "moderate" to "high" category for influenza cases, with Piscataquis and Washington counties in the "very high" category. About 90% of influenza activity is the influenza A strain, and the remaining 10% is influenza B.
There have not been any recorded human cases of bird flu in Maine and no reported domesticated animal cases in 2025. However, Maine has had some cases of bird flu reported in wild animals, and state officials have warned people with chickens, ducks or other domesticated birds to take precautions.
Federal data lags state data by one week, but according to the most recent U.S. CDC data, Maine and much of the nation is considered to have "very high" levels of flu, with the only exceptions being some states in the Midwest and West, including Utah, Nevada and Arizona.
The flu is circulating at the same time as other respiratory illnesses.
Maine is reporting "high" levels of COVID-19 in wastewater, down from "very high" in late January. RSV and norovirus were also reportedly circulating at high levels in Maine this winter, although there is not a robust data tracking of those viruses.
The best way to prevent influenza is to get a flu shot, and it is not too late to get vaccinated. Many places offer flu shots, including primary care offices, pharmacies and other health care settings. Public health experts say to take other measures to prevent illness and the spread of flu, such as frequent hand washing, staying home when sick and avoiding crowded, indoor gatherings.
Influenza symptoms include fever and chills, cough, sore throat, muscle aches, headache, fatigue and a runny nose.
Copy the Story Link
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Vox
4 hours ago
- Vox
RFK Jr.‘s mass firing of the government's vaccine experts, explained
covers health for Vox, guiding readers through the emerging opportunities and challenges in improving our health. He has reported on health policy for more than 10 years, writing for Governing magazine, Talking Points Memo, and STAT before joining Vox in 2017. For the past 60 years, a committee of independent experts has advised the federal government on vaccine policy, providing guidance on which shots people should get and when. Government public health officials have almost always followed the panel's recommendations, all but making it the final word on public health policy in the US for most of its existence. And over those decades, the United States has made tremendous health gains over that time through mass vaccination campaigns. But on Monday, Health Secretary Robert F. Kennedy Jr. fired every sitting member of the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP), a move that stunned doctors and scientists across the country. And it means that the CDC's days as the clear and unchallenged authority on US vaccine policy appear numbered. 'Up until today, ACIP recommendations were the gold standard for what insurers should pay for, what providers should recommend, and what the public should look to,' Noel Brewer, a health behavior professor at the University of North Carolina, who was a member of the panel until this week, told the Associated Press. 'It's unclear what the future holds.' Today, Explained Understand the world with a daily explainer plus the most compelling stories of the day, compiled by news editor Sean Collins. Email (required) Sign Up By submitting your email, you agree to our Terms and Privacy Notice . This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. New committee members will be announced at some point, but as of Tuesday morning, even top US senators did not know who the replacements would be. The panel is supposed to hold one of its periodic public meetings in late June to discuss the Covid-19 vaccine, as well as shots for RSV and HPV, among others. This is a watershed moment in US public health, one that seems sure to sow confusion among patients and health care providers. The deepening divide between Kennedy's Make American Healthy Again (MAHA) movement and mainstream medicine could make it harder for people who want vaccines to get them, while encouraging more doubt about the value and safety of shots among the general public. Here's what you need to know. Why is Kennedy doing this? The vaccine advisory committee was first convened by the surgeon general in 1964, but it is not enshrined in federal law. That means that Kennedy — as the top official at the US Department of Health and Human Services, which contains the CDC — can change its membership or dissolve the panel entirely if he so desires. Kennedy framed his decision to clear out the members as necessary to restore public trust in the government's vaccine recommendations. In a Wall Street Journal op-ed, Kennedy asserted the committee 'has been plagued with persistent conflicts of interest and has become little more than a rubber stamp for any vaccine.' As health secretary, he has made overhauling vaccine policy a centerpiece of his agenda, both through his rhetoric and policy. Over the past few months, while the worst measles outbreak in 30 years has spread through the US, Kennedy has equivocated in public comments on the value of the measles vaccine, which doctors say is far and away the best tool to combat the disease. He directed an anti-vaccine researcher to scour federal data for evidence of a vaccine-autism link. His department's recent MAHA report on childhood chronic disease named vaccines as one example of how the US overmedicalizes its children and exposes them to artificial agents that could do harm to their body. Then in late May, Kennedy oversaw a revision of the federal government's Covid-19 vaccine guidance, limiting the shots to elderly people and those who are immunocompromised. He ended the recommendation that pregnant women and kids get a Covid vaccine shot, even though studies have shown they help confer immunity to infants, who are at a higher risk from the virus and cannot be vaccinated until they are 6 months old. The move plainly circumvented ACIP's accepted role in setting vaccine policy, presaging this week's mass firing. Whatever his intentions, Kennedy's gutting of the federal vaccine committee seems likely to sow even more distrust — and certainly more confusion. People are reasonably left to wonder whether they can trust forthcoming CDC guidance on vaccines, and just what vaccines they'll be able to get. How will I know which vaccines to get? In the past, ACIP would typically meet a few times a year to discuss any additions or changes to the country's vaccine schedule. Their recommendations have usually been adopted without alterations by the CDC director, and then became the standard for state and local health departments across the country. Importantly, most health plans are required to cover any shots that the committee recommends. Now there is far more uncertainty. Will doctors follow the CDC guidance, even if it changes under a new advisory panel staffed by Kennedy loyalists, or will they stick with the earlier vaccine schedule? Will health insurance plans cover the cost of a vaccine that professional medical organizations support but the CDC does not? Once-unthinkable questions could soon be something doctors and patients must deal with every day. Some doctors already believed, before the firings at ACIP, that the CDC was no longer trustworthy under Kennedy's leadership; his unilateral change to the Covid vaccine guidance in May was enough to convince them. In a media call last week, experts from the Infectious Disease Society of America urged patients and providers in the short term to consult with professional medical societies — not the CDC — on vaccine recommendations. They considered those groups, as well as guidance from European health authorities, the best substitutes we currently have for information on vaccines if the CDC's recommendations can no longer be taken at face value. 'It's been a confusing several days, confusing last two weeks, and I'm not sure that confusion is going to be abated in the near future,' John Lynch, an infectious disease doctor at the University of Washington, said on the call. 'These are evidence-based guidelines developed by experts in the field using transparent methods and published publicly,' Lynch said. Kennedy, in explaining his change to the Covid vaccine guidelines, said he wanted to encourage shared decision-making between providers and their patients. The CDC guidance would be only one consideration in the decision whether to vaccinate, rather than a firm recommendation. The doctors from the IDSA said that such conversations are already to be considered best practice among physicians — and noted Kennedy's undermining of trust in the federal vaccine policy would now make them more important. 'I would just emphasize the need to have a good source of information when this situation occurs. If indeed shared decision making is going to occur, we always do our research,' Dr. Flor Muñoz-Rivas at Baylor College of Medicine said. 'But go to the proper sources.' What are the long-term risks? There is a lot we don't know right now: Who will be named to the new panel? Will they change existing vaccine recommendations? Will they approve new ones? But the experts warned that Kennedy's rhetoric alone risks undermining people's confidence in vaccinations. 'All health care decisions are shared decision-making; this is not a special concept that's only rolled out for conversations like vaccination,' Lynch said on the IDSA call. 'As an infectious disease doctor, when I talk to a patient about treatment or diagnostics, it is a conversation. It is shared decision-making.' Kennedy has quickly disrupted decades of public health consensus. Anyone who watched the sometimes contentious ACIP meetings during the pandemic saw the members grappling with genuinely vexing questions about who should be prioritized for vaccination in a public health emergency. The pandemic featured rare examples of Biden CDC director Rochelle Walensky overruling the panel in certain cases in which the experts actually recommended against more vaccinations. (Walensky said she overrode the guidance to align the CDC with a separate recommendation from the FDA's advisory committee, and cited the narrow 9-6 vote against the recommendation.) Those scenes should have helped dispel the notion that they were acting as a rubber-stamp for any new shot Big Pharma produced. But the nation's top health official is now telling Americans that they should never have trusted the ACIP, which risks pushing more people to skip routine immunization. Shortly after the country declared measles eradicated in 2000, 94 percent of adults said childhood immunizations were extremely or very important. But that consensus has since weakened: 69 percent of Americans said the same in 2024. If changing opinion leads to declining vaccination rates, diseases that we successfully stamped out through vaccines to rebound — which is exactly what we are seeing now with measles. The US is experiencing its highest number of measles cases since the 1990s, nearing 1,200 as of this writing. One outbreak that accounts for most of those cases took off in a small Texas community where vaccination rates had fallen far below the 95-percent threshold that is considered necessary to stop the virus's spread. Other knock on effects could hurt Americans who still want to get vaccinated. Pharma companies, the target of so much of Kennedy's criticism, could decide to stop pursuing new vaccines if they believe the federal government will limit access as much as possible, shrinking the world's biggest pharmaceutical market. Vaccines are not big moneymakers for drug companies, and they have often relied on the US government's support to develop new ones. Kennedy, however, has canceled major vaccine development contracts during his first few months as health secretary, including a $700 million contract with Moderna, one of two companies that produced the mRNA Covid vaccines, to work on a universal flu shot. Kennedy has quickly disrupted decades of public health consensus. For now, the best reaction is, oddly enough, for patients and providers to take him at his word when he says people should not take medical advice from him — and make their own decisions in collaboration with their doctors.
Yahoo
16 hours ago
- Yahoo
Newly approved therapy could offer another option for protecting infants from RSV, a common infection that can be deadly
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that's the No. 1 cause of hospitalization in infants. The US Food and Drug Administration has approved a new monoclonal antibody to help prevent infection, according to an announcement late Monday from drugmaker Merck. The therapy, Enflonsia, is designed to be given in a single 105-milligram shot to protect newborns and infants from mild, moderate or severe RSV through all five months of their first virus season, which typically starts in the fall and goes through the next spring. Study materials that Merck submitted to the FDA for its approval showed that the antibody had a similar safety profile as a placebo. The most common adverse reactions from Enflonsia were mild and included injection-site swelling and a rash in a small number of infants. In a mid- to late-stage trial, Enflonsia reduced RSV-associated hospitalizations in infants more than 84% compared with a placebo. RSV can sometimes turn into serious lower respiratory infections like pneumonia, but the shot also reduced lower respiratory infections that needed medical attention by more than 60% compared with a placebo. 'Enflonsia provides an important new preventive option to help protect healthy and at-risk infants born during or entering their first RSV season,' Dr. Dean Y. Li, president of Merck Research Laboratories, said in a news release. 'We are committed to ensuring availability of Enflonsia in the US before the start of the upcoming RSV season to help reduce the significant burden of this widespread seasonal infection on families and health care systems.' Merck says it hopes Enflonsia will be available before the start of the 2025-26 respiratory virus season. First, it needs to be recommended by the US Centers for Disease Control and Prevention, and that means going in front of the agency's Advisory Committee on Immunization Practices. It's on the agenda for the panel's meeting this month, but US Health and Human Services Secretary Robert F. Kennedy removed all the members of that committee Monday. He says he will appoint new ones, but it's unclear how long that process will take. Doctors say another tool to prevent RSV cannot come soon enough. RSV is ubiquitous, one of the most common causes of childhood illness. Most kids will catch this highly contagious respiratory virus at some point before they turn 2, according to the CDC. For many healthy adults and older kids, RSV causes a mild illness like a cold. Typically, symptoms can be managed at home, and they often go away on their own. But for infants and the elderly, it can be a different story. Very young children's immune systems are just starting to learn how to fight infections, and infants have tiny airways. RSV inflames those airways, making it difficult to breathe, and can turn into a serious lower respiratory illness like bronchiolitis or pneumonia. Some of these RSV infections can be deadly. Two to three percent of infants under 6 months are hospitalized with RSV in the US every year, according to the CDC. Among children younger than 5, about 58,000 to 80,000 are hospitalized due to RSV. There's no specific medicine to treat RSV. Doctors can give an infant supportive care and oxygen, and then they essentially wait until their oxygen levels get back to normal, said Dr. Amy Edwards, director of pediatric infection control at UH Rainbow Babies and Children's Hospital in Cleveland. 'I hate RSV,' said Edwards, who was not connected with the Merck trial. 'Just to watch them struggle to breathe, and then they get scared, and then they cry, which of course makes the breathing worse, and their little lips turn blue. It's just so hard to watch.' Enflonsia joins a handful of other tools recently made available to protect babies from, although the FDA put RSV vaccine trials involving infants and young children ages 2 to 5 on hold last year after some developed severe illness. To prevent RSV in infants, the CDC currently recommends an RSV antibody made by Sanofi and AstraZeneca, called Beyfortus, which was approved in 2023. It was in short supply during that year's RSV season, although Edwards said supply started to catch up with demand in her health care system last season, and the company pledged to produce more. The other option to protect an infant is a vaccine that a person can get during pregnancy. Together, Beyfortus and the vaccine have made a difference. A CDC study published in March found that RSV-associated hospitalization rates among infants up to 7 months during 2024-25 season were lower than in seasons when those therapies weren't available. Edwards just hopes people will get protection for their infants. 'Every RSV season fills us to the gills,' she said. 'This should theoretically empty us out, if we have good uptake.'
WebMD
16 hours ago
- WebMD
FDA OKs New Shot to Protect Babies Against RSV
June 10, 2025 – The FDA has approved a new shot to prevent respiratory syncytial virus (RSV) infection in babies during their first RSV season, which typically lasts from fall through spring. Clesrovimab, which is sold as Enflonsia, is the first and only RSV protection for babies that uses the same dose for all infants, regardless of their body weight. This makes it a simpler and more precise option that ensures reliable protection throughout the RSV season. RSV is a common virus that spreads during colder months through coughs, sneezes, direct contact, or contaminated surfaces. It typically causes mild, cold-like symptoms. Infants (especially those under 6 months) and older adults are more likely to have a severe RSV infection. RSV can cause bronchiolitis (inflammation of small airways) and pneumonia, sometimes leading to hospitalization. Because it's the leading cause of hospitalization in infants, vaccines and preventive treatments are the best way to protect them. Merck, the maker of the new preventive, said the FDA's decision was based on two clinical trials. In the first trial, a single dose of Enflonsia was given to newborns, both preterm and full-term, and reduced RSV severe lung infections by 60% and hospitalizations by 84% over five months, compared to a placebo. The second trial showed Enflonsia was as effective and safe as an older RSV medicine (palivizumab) for babies at higher risk, such as those born very early or with lung or heart issues. The clinical trials also showed that Enflonsia was just as safe on its own or with other routine childhood vaccines. "Enflonsia combines dosing convenience with strong clinical data showing significant reductions in RSV disease incidence and hospitalizations, making it a promising new intervention to help protect infants from RSV," Octavio Ramilo, MD, chair of the Department of Infectious Diseases at St. Jude Children's Research Hospital and investigator for the clinical trials, said in a statement. The Enflonsia shot contains ready-made antibodies that help newborns and infants fight off RSV before it can cause serious lung infections. It uses a single, non-weight-based, 105-mg dose that gives fast and lasting protection for about five months. Babies born during RSV season should get the shot at birth, while those born before the season should get it just before it starts. The preventive is given as an injection in the baby's thigh.
